Novel molecular mechanism driving neuroprotection after soluble epoxide hydrolase inhibition: Insights for Alzheimer's disease therapeutics
CNS Neuroscience & Therapeutics · 2024
DOI: 10.1111/cns.14511 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2024. Verfasst von Christian Griñán-Ferré und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Therapeutic Chemistry, Institut de Neurociències-Universitat de Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Alzheimer Disease, Epoxide Hydrolases. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agència de Gestió d'Ajuts Universitaris i de Recerca, Ministerio de Ciencia e Innovación, Spanish Ministerio de Ciencia e Innovación.
Themen: Demenz
Abstract (Originalsprache)
Background
Neuroinflammation is widely recognized as a significant hallmark of Alzheimer's disease (AD). To combat neuroinflammation, the inhibition of the soluble epoxide hydrolase (sEH) enzyme has been demonstrated crucial. Importantly, sEH inhibition could be related to other neuroprotective pathways described in AD.
Aims
The aim of the study was to unveil new molecular pathways driving neuroprotection through sEH, we used an optimized, potent, and selective sEH inhibitor (sEHi, UB‐SCG‐51). Materials and Methods UB‐SCG‐51 was tested in neuroblastoma cell line, SH‐SY5Y, in primary mouse and human astrocytes cultures challenged with proinflammatory insults and in microglia cultures treated with amyloid oligomers, as well as in mice AD model (5XFAD).
Results
UB‐SCG‐51 (10 and 30 μM) prevented neurotoxic reactive‐astrocyte conversion in primary mouse astrocytes challenged with TNF‐α, IL‐1α, and C1q (T/I/C) combination for 24 h. Moreover, in microglial cultures, sEHi reduced inflammation and glial activity. In addition, UB‐SCG‐51 rescued 5XFAD cognitive impairment, reducing the number of Amyloid‐β plaques and Tau hyperphosphorylation accompanied by a reduction in neuroinflammation and apoptotic markers. Notably, a transcriptional profile analysis revealed a new pathway modulated by sEHi treatment. Specifically, the eIF2α/CHOP pathway, which promoted the endoplasmic reticulum response, was increased in the 5XFAD‐treated group. These findings were confirmed in human primary astrocytes by combining sEHi and eIF2α inhibitor (eIF2αi) treatment. Besides, combining both treatments resulted in increased in C3 gene expression after T/I/C compared with the group treated with sEHi alone in cultures.
Discussion
Therefore, sEHi rescued cognitive impairment and neurodegeneration in AD mice model, based on the reduction of inflammation and eIF2α/CHOP signaling pathway.
Conclusions
In whole, our results support the concept that targeting neuroinflammation through sEH inhibition is a promising therapeutic strategy to fight against Alzheimer's disease with additive and/or synergistic activities targeting neuroinflammation and cell stress.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Therapeutic Chemistry, Institut de Neurociències-Universitat de Barcelona, Barcelona, Spain.
- Centro de Investigación en Red, Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.
- Laboratory of Medicinal Chemistry (CSIC Associated Unit), Faculty of Pharmacy and Food Sciences, Institute of Biomedicine (IBUB), University of Barcelona (UB), Barcelona, Spain.
- Institut d'Investigacions Biomèdiques de Barcelona (IIBB), Consejo Superior de Investigaciones Científicas (CSIC), Barcelona, Spain.
- Neuraly Inc., Maryland, Gaithersburg, USA.
ORCID-Profile: Mercè Pallàs
Förderung
- Agència de Gestió d'Ajuts Universitaris i de Recerca
- Ministerio de Ciencia e Innovación
- Spanish Ministerio de Ciencia e Innovación
- María de Maeztu Unit of Excellence to Institute of Neurosciences
- AGAUR Catalonia
Zitieren
APA
Griñán-Ferré, C., Jarné-Ferrer, J., Bellver-Sanchís, A., Codony, S., Puigoriol-Illamola, D., Sanfeliu, C., Oh, Y., Lee, S., Vázquez, S., & Pallàs, M. (2024). Novel molecular mechanism driving neuroprotection after soluble epoxide hydrolase inhibition: Insights for Alzheimer's disease therapeutics. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.14511
Vancouver
Griñán-Ferré C, Jarné-Ferrer J, Bellver-Sanchís A, Codony S, Puigoriol-Illamola D, Sanfeliu C, et al. Novel molecular mechanism driving neuroprotection after soluble epoxide hydrolase inhibition: Insights for Alzheimer's disease therapeutics. CNS Neuroscience & Therapeutics. 2024. doi:10.1111/cns.14511
BibTeX
@article{GrinFerr2024,
author = {Griñán-Ferré, Christian and Jarné-Ferrer, Júlia and Bellver-Sanchís, Aina and Codony, Sandra and Puigoriol-Illamola, Dolors and Sanfeliu, Coral and Oh, Yumin and Lee, Seulki and Vázquez, Santiago and Pallàs, Mercè},
title = {Novel molecular mechanism driving neuroprotection after soluble epoxide hydrolase inhibition: Insights for Alzheimer's disease therapeutics},
journal = {CNS Neuroscience & Therapeutics},
year = {2024},
doi = {10.1111/cns.14511}
}
EUVIMED